APA (7th ed.) Citation

Strowitzki, T. (2016). Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: A phase 3 open-label follow-up to main study. BioMed Central. https://doi.org/10.1186/s12958-016-0164-y

Chicago Style (17th ed.) Citation

Strowitzki, Thomas. Safety and Efficacy of Ovaleap® (recombinant Human Follicle-stimulating Hormone) for Up to 3 Cycles in Infertile Women Using Assisted Reproductive Technology: A Phase 3 Open-label Follow-up to Main Study. London: BioMed Central, 2016. https://doi.org/10.1186/s12958-016-0164-y.

MLA (9th ed.) Citation

Strowitzki, Thomas. Safety and Efficacy of Ovaleap® (recombinant Human Follicle-stimulating Hormone) for Up to 3 Cycles in Infertile Women Using Assisted Reproductive Technology: A Phase 3 Open-label Follow-up to Main Study. BioMed Central, 2016. https://doi.org/10.1186/s12958-016-0164-y.